未知机构：加科思panKRAS价值重估空间巨大panKRAS抑制剂-20260304

Summary of Conference Call Notes Company and Industry Involved - The notes pertain to 加科思 (Gakos), focusing on its pan-KRAS inhibitors and advancements in the oncology sector. Core Points and Arguments - Progress of pan-KRAS Inhibitors: The clinical data for RMC-6236 is reported as excellent, leading to a market capitalization increase of over $20 billion for Revolution [1] - Initial Data for JAB-23E73: The preliminary data for Gakos' pan-KRAS inhibitor JAB-23E73 shows significant safety advantages, with no grade 3 toxicity observed at the escalated dose level and a skin toxicity incidence of 10% (all grade 1). In comparison, RMC-6236 has a skin toxicity rate of 90% with 8% grade 3 toxicity [1] - Collaboration with AstraZeneca: A collaboration worth $2 billion with AstraZeneca is expected to accelerate global progress through combination therapy approaches (IO/ADC, etc.) [1] - Next-Generation ADC Platform: The next-generation ADC platform is noted to have multi-target and multi-indication expansion potential, with the first candidate drug, EGFRG12DitADC, having its PCC confirmed and an IND submission expected in H2 2026 [1] Additional Important Content - iADC Candidate Drug: The first candidate drug for iADC, HER2-STINGiADC, has also confirmed its PCC, with an IND submission anticipated in H2 2026 [2] - KRAS G12C Inhibitor: The KRAS G12C inhibitor, Goretinib, has entered the medical insurance coverage, showing rapid volume growth. Clinical registrations are ongoing for its combination with SHP2 inhibitors in pancreatic and colorectal cancers [2] - Valuation and Rating: Based on risk-adjusted DCF calculations, the company is valued at HKD 8.912 billion, corresponding to a target price of HKD 11.26, with a "strong buy" rating [2]